Selux Diagnostics, Inc., Preventing superbug infections and antimicrobial resistance (AMR) is the objective of this biotech company. Leading the round were RA Capital Management, with Schooner Capital, Sands Capital, and Northpond Ventures participating.
The money will be used by the company to begin the next stage of the Selux Next Generation Phenotyping (NGP) System’s commercialization in the US.
Selux Diagnostics, under the direction of CEO Steve Lufkin, is expediting the process of selecting individualised antimicrobial medication for every patient with an infectious condition.
Read also – Blue Yonder deaclares an Agreement To Acquire One Network Enterprises
This additional funding comes after the company announced that it has received its third FDA 510(k) clearance for its direct from Positive Blood Culture Separator. This clearance allows the company to offer a single platform that can deliver fast AST results for isolated colonies as well as positive blood cultures.
Fast Antibiotic Susceptibility Testing (AST) is made possible by the Selux NGP System, which can provide same-day AST findings. This will improve patient care and lessen the overuse of broad spectrum antibiotics, which is a key contributing reason to the rise in superbugs.
About Selux Diagnostics
Selux Diagnostics is working on a Next Generation Phenotyping (NGP) platform that will significantly improve the speed and precision of prescribing targeted, individualised antibiotic medicines, potentially revolutionising the treatment of infectious disease patients. Timely and more informed treatment decisions have the potential to prevent antibiotic resistance worldwide, save lives, enhance patient outcomes, shorten hospital stays and hospital-acquired infections, and improve patient outcomes.
Read also – Boston-based InStride Health Secures $30Million in Series B Round Funding
